UBS lowered the firm’s price target on Hologic (HOLX) to $84 from $90 and keeps a Neutral rating on the shares. The firm updated models in the life science sector following management meetings.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOLX:
- Salesforce upgraded, ServiceNow downgraded: Wall Street’s top analyst calls
- Hologic initiated with a Peer Perform at Wolfe amid near-term headwinds
- Hologic initiated with a Peer Perform at Wolfe Research
- Cervical cancer recommendations lift ‘minor overhang’ on Hologic, says Leerink
- USPSTF draft guidance on cervical cancer positive for Hologic, says BTIG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
